Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Active not recruiting 2Terminated 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Thoracic 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Mesothelioma, Malignant 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma 1Ataxia Telangiectasia 1

Interventions

Paclitaxel 68Carboplatin 64pembrolizumab 32Cyclophosphamide 32Bevacizumab 27liposomal doxorubicin 24Cisplatin 24Topotecan 21Gemcitabine 21olaparib 18fludarabine 17Taxes 16Docetaxel 15Nivolumab 14Doxorubicin 14niraparib 13veliparib 12Albumin-Bound Paclitaxel 11aldesleukin 9Filgrastim 9fludarabine phosphate 8durvalumab 8Oxaliplatin 8Fluorouracil 8Drug Therapy 8sargramostim 7Peripheral Blood Stem Cell Transplantation 7Magnetic Resonance Spectroscopy 7Leucovorin 7talazoparib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Ovarian Neoplasms × BAY 1895344 × Clear all
NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
74 enrolled
BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

NCT04616534 2025-05-22

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
14 enrolled
GastrointestinalGynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

NCT04267939 2023-12-21

ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

Bayer

Phase 1 Terminated
14 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡